International Stem Cell Corp. (ISCO) Fact Sheet - page 1

Select Financials
International Stem Cell Corporation (ISCO)
specializes in the therapeutic applications of
human stem cells and the development and commercialization of cell-based biomedical
products. The company was the first to develop and perfect a new class of human stem cells
called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent
portfolio offering clean intellectual property and freedom to operate.The company’s stem cells can
be used in millions of people regardless of sex or racial background, with potentially minimal
expectation of immune rejection after transplantation.
The company’s human stemcells have been shown to be as pluripotent as embryonic stem cells,however
their creation does not involve the destruction of a viable human embryo effectively sidestepping
the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In
contrast to induced pluripotent stem cells (iPS),ISCO’s stem cells do not involve manipulation of cells’
genome thereby avoiding potential safety and regulatory
obstacles associated with iPS technology.
Fiscal Year End
December 31
Market Cap (6/30/2013)
$25.9M
Enterprise Value (6/30/2013)
$30.2M
Current Price (6/30/2013)
$0.23
52-Week Price Range
$0.17 - $0.39
Shares Outstanding
132.6M
Avg. Volume (3 month)
298,075
Revenue (TTM)
$4.57M (as of 12/31/2012)
All financial information as of the date
indicated unless otherwise stated.
Neuronal cell derived from hpSC
Industry:
Healthcare
Sector:
Biotechnology
Exchange:
OTCQB
Ticker:
ISCO
International Stem Cell Corporation
5950 Priestly Drive
Carlsbad, CA 92008
760-940-6383
Company Contact:
Simon Craw, PhD
Executive Vice President
760-653-1206
Investor Relations:
MZ Group
Mark McPartland
212-301-7130
Investment Highlights
• Leader in human stem cells with proprietary platform technology.
• Therapeutic programs focused on high value market opportunities.
• Broad patent portfolio offering strong protection and freedom to operate.
• Biomedical subsidiaries delivering revenues and synergistic infrastructure.
The company’s scientists are currently focused on using its stem cells to treat severe unmet medical
needs where cell therapy has been clinically proven but is limited due to the unavailability of safe
human cells. Once clinically validated there are an essentially unlimited number of potential
applications and partnership opportunities. For a list of recent scientific publications go to www.
internationalstemcell.com/scientific_publications.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two
wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells
and growth media for biological research, and Lifeline Skin Care, the company manufactures and
markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology.
Research and Development
TARGET
1st GOAL
MEDICAL NEED MARKET SIZE
Treatment of
Parkinson’s
1 Million Sufferers
in U.S
$2.5 Billion
Treatment of Liver
Damage
30k Deaths
Annually in U.S.
$1.0 Billion
Produce Cornea
Tissue Implants
10 Million in Need
of Transplant
$1.0 Billion
Scientific Accomplishments
• Developed small molecule based direct differentiation methods to produce highpurity popula-
tions of cells for therapeutic use in a controlled manner. Designed to efficiently generate the
quantity and quality required for clinical use.
• Successfully created dopaminergic neurons to treat Parkinson’s disease. Shown in rodent models
that the neuronal cells engraft and produce dopamine.
• Demonstrated the ability to create human hepatocyte-like cells that engraft,mature and express
human liver proteins in rodent models.
• Produced self-assembling human corneas which include all the necessary layers and could be
used as corneal transplants or drug toxicology testing
1 2
Powered by FlippingBook